Hormonal
Once-weekly subcutaneous semaglutide at 2.4mg reduces the risk of major adverse cardiovascular events (MACE) in overweight or obese individuals with cardiovascular disease who do not have diabetes.
For overweight or obese individuals with cardiovascular disease but no diabetes, once-weekly subcutaneous semaglutide at 2.4mg is being studied for its ability to reduce cardiovascular events. While results from the SELECT trial were pending at the time of this review, the mechanism suggests potential cardiovascular benefits beyond glucose control.
The SELECT study commenced in 2018 and is a randomised, double-blind, placebo-controlled trial to determine the impact of semaglutide 2.4mg QW on cardiovascular outcomes in overweight or obese participants with cardiovascular disease who do not have diabetes (29).
Why this rating
The paper states the trial is ongoing ('due to enrol around 17,500 participants with estimated completion in 2023'), so no final results are provided.
Source
Recent developments in <scp>GLP‐1RA</scp> therapy: A review of the latest evidence of efficacy and safety and differences within the class
Evie Bain et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14487
More from this paper
- Once-weekly subcutaneous semaglutide at 2.4mg induces significant weight loss (mean 14.9%) in adults with obesity, significantly outperforming placebo.Strong
- Once-weekly subcutaneous semaglutide at 1.0mg significantly lowers HbA1c and promotes weight loss in patients with Type 2 Diabetes compared to other glucose-lowering therapies.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →